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• Clinically irrelevant.
• Only proposed as a research framework for 
early intervention with disease modifying 
therapy.
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• Conclusive identification of the underlying 
cause of the cognitive impairment by 
biomarkers and the onset of the earliest 
cognitive symptoms.
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• Abnormalities in multiple domains that are 
severe enough to produce loss of function 
BIOMARKERS
Fig 4. Model for biomarkers during the development of AD. [4]
Fig 3. Validation of new candidates as biomarkers. [3]
CSF MARKERS OF AD
Fig 1. Pathological cascades and biomarkers of AD. [1]
Fig 2. Aspect of a healthy and an AD neuron. [2]
Fig 5. Longitudinal metabolic reductions on FDG-PET.[5]
CSF Total-tau (T-tau)
CSF Phosphorylated-tau (P-tau)
CSF Aβ isoforms (Aβ40/Aβ42)
Pathogenic events change a soluble protein
to its insoluble aggregated form which
makes up neurofibrillary tangles.
The concentration of tau protein in CSF
reflects the intensity of neuronal
degeneration in chronic neurodegenerative
disorders.
In some chronic neurodegenerative
disorders the protein undergoes
hyperphosphorylated at many sites. As a
result of this aberrant phosphorylation the
protein loses its ability to act as a “glue”
promoting the aggregation of tau with
subsequent formation of NFTs.
Aβ is a cleavage product from the amyloid
precursor protein (APP) which is generated
as a soluble protein during normal cellular
metabolism and is secreted to CSF.
Fig 6. Schematic drawing of Aβ isoforms formation. [6]
USE OF CSF BIOMARKERS IN THE DIAGNOSIS
Table 1. CSF biomarkers in AD and other dementias diagnosis.
CSF BIOMARKERS IN AD TREATMENT
The major pathological hallmarks of the disease are the loss and the degeneration of
neurons and synapses due to brain amyloid plaques and intraneuronal neurofibrillary
tangles (NFTs).
Alzheimer’s disease (AD) is a slowly progressive neurodegenerative disorder characterized
by significant cognitive deficits, behaviour changes and a progressive loss of functional
autonomy together with impaired judgement, decision-making and orientation.
There is a great need for biochemical markers (biomarkers) that could aid early diagnosis
of AD and distinguish between AD, MCI and other dementia types. This project focuses
on established biomarkers, those that have been evaluated in several studies by different
research groups.
A biomarker is a physiological, biochemical or anatomic parameter that measures specific
hallmarks of disease-related pathological changes and guides clinical diagnosis and
treatment. An ideal candidate biomarker for AD should reflect the neuronal and synaptic
degeneration.
A diagnostic biomarker should be highly specific and it should predict the pathological
processes precisely and it should also reflect the degree of response to treatment.
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CSF Aβ42 and CSF tau have stood the test of
time being potential predictors of cognitive
decline and future dementia.
The most efficient AD treatment may be a
multi-modal drug such Cerebrolysin (CBL),
CBL is a brain derived peptide preparation
purified from pig brains.
Collaborations between geriatricians,
neuroimaging specialists, neuropsychiatrists
and molecular and cellular neurobiologists
are being promoted.
FUTURE PERSPECTIVES
CONCLUSIONS
• Biomarkers increase the diagnosis accuracy.
• Further discovery and validation of CSF biomarkers is essential to improve early diagnosis 
and accelerate the development of new therapies.
• There are three main uses of biomarkers in clinical trials:
- As diagnostic tools to exclude between AD dementia, MCI due to normal aging and other dementias.
- To identify and monitor the biochemical effect of a drug to facilitate its development.
- To allow early and specific detection of side effects of the drug.
• Early diagnosis can be thought of as an opportunity for patients to plan for future.
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